Date Posted: 23 Feb 2011
Summary: “The debate is over: AMS provides the route to better drug development paradigms / protocols.”
Dennis A. Smith, Pfizer Worldwide Research & Development
Download:

Please complete the following for access to the download

Name:
Email:
 

“The debate is over: AMS provides the route to better drug development paradigms / protocols.”
Dennis A. Smith, Pfizer Worldwide Research & Development

This resounding affirmation of Accelerator Mass Spectrometry (AMS) comes from a pharmaceutical industry thought-leader in response to an Astra Zeneca-GSK-HLS-Xceleron white paper published in the February 24 edition of Bioanalysis. In the attached papers, we have created a robust framework to apply this very specific and sensitive analytical technique in a way that enables innovative and highly cost-effective clinical investigations.

Novel analytical techniques employed to meet the demands of translational medicine must be applied with the rigor expected by the regulated pharmaceutical industry. These position papers address the challenges and propose a robust approach to method validation for LC AMS.

Click to see more news